Thymalin vs VIP
A side-by-side research comparison of Thymalin and VIP across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Thymalin | VIP |
|---|---|---|
| Full name | Thymalin (Thymus Extract Peptide) | Vasoactive Intestinal Peptide |
| Category | Immune Support | Immune Support |
| Status | Research compound | Research compound |
| Mechanism | Contains bioactive thymic peptides that regulate T-lymphocyte differentiation, restore T-helper/T-suppressor ratios, and enhance phagocyte activity and interferon production. | Activates VPAC1 and VPAC2 receptors, raising intracellular cAMP. This dampens pro-inflammatory cytokine production, supports vasodilation and pulmonary function, and modulates regulatory T-cell activity. |
| Molecular weight | ~1000-5000 Da (complex mixture) | ~3326 Da |
| Half-life | ~4-6 hours | Very short (~1-2 minutes in plasma) |
| Bioavailability | ~80% intramuscular | Intranasal (most common in protocols); rapidly degraded systemically |
| Typical dose | 5-10 mg | ~50 mcg per spray |
| Frequency | Daily for 5-10 days | 1-4x daily |
| Route | Intramuscular injection | Intranasal spray |
Thymalin reported benefits
- Immune reconstitution
- T-cell ratio normalization
- Interferon production
- Anti-tumor immunity support
VIP reported benefits
- Broad anti-inflammatory effect
- Supports pulmonary and vascular function
- Immune modulation (regulatory T cells)
- Used in chronic inflammatory response protocols
Related comparisons
Research and educational reference only. Not medical advice.